• Immutep received a US patent covering eftilagimod alfa combinations with PD-1 pathway inhibitors, expanding protection for its efti-based therapies.
• The grant brings its US patent holdings in this family to five.
• Protection expires March 23, 2038, including 806 days of patent term adjustment.
• A continuation application was filed to pursue additional embodiments of the invention.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101848PRIMZONEFULLFEED9875102) on November 10, 2026, and is solely responsible for the information contained therein.